Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug approved in Europe in 2006 but was withdrawn worldwide...
14 KB (1,176 words) - 03:25, 9 October 2024
Cannabinoid receptor antagonist (section Rimonabant)
receptor antagonists. The first CBR inverse agonist, rimonabant, was described in 1994. Rimonabant blocks the CB1 receptor selectively and has been shown...
41 KB (4,204 words) - 03:27, 9 October 2024
at the CB1 cannabinoid receptor. AM-251 is structurally very close to rimonabant; both are biarylpyrazole cannabinoid receptor antagonists. In AM-251,...
5 KB (339 words) - 15:53, 7 September 2024
oxaloacetate supplements had no effect on lifespan in healthy laboratory mice. Rimonabant (Acomplia) is an anti-obesity drug initially approved for use in the European...
23 KB (2,847 words) - 12:04, 25 March 2024
cannabis), increased appetite. However, some drugs in this class such as rimonabant were withdrawn or ceased development to concerns about mental health and...
53 KB (4,991 words) - 18:16, 16 September 2024
drugs that were ever approved by the FDA. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran and ximelidine, for example) were approved to...
45 KB (1,903 words) - 16:52, 9 October 2024
selective for the CB1 receptor over CB2, than the more commonly used ligand rimonabant, with a Ki at CB1 of 350fM (i.e. 0.00035nM) and a selectivity of over...
5 KB (331 words) - 15:26, 19 February 2024
The antihypertensive effect of spilanthol was blocked by CB1 antagonist rimonabant and TRPV1 antagonist capsazepine, suggesting spilanthol mediates some...
5 KB (454 words) - 15:39, 7 August 2024
discontinued following the problems seen during clinical use of the similar drug rimonabant. Cannabinoid receptor antagonist Kim MA, Yun H, Kwak H, Kim J, Lee J (2008)...
4 KB (149 words) - 09:08, 9 September 2024
seen with an antagonist. An example is the cannabinoid inverse agonist rimonabant. A superagonist is a term used by some to identify a compound that is...
14 KB (1,622 words) - 03:21, 4 September 2024
O-1918 O-2050 O-2654 Otenabant (CP-945,598) PF-514273 PipISB PSB-SB-487 Rimonabant (SR141716) Rosonabant (E-6776) SR-144,528 Surinabant (SR147778) Taranabant...
165 KB (17,231 words) - 02:21, 11 November 2024
the psychiatric side effects in humans which led to the withdrawal of rimonabant from the market. Its antiobesity effects are believed to be mediated by...
6 KB (528 words) - 04:30, 17 September 2024
Protriptyline Proparacaine Quetiapine Ramelteon Rasagiline Reboxetine Ribavirin Rimonabant Risperidone Rivastigmine Rofecoxib Ropinirole Rotigotine Rufinamide Selegiline...
26 KB (1,722 words) - 09:50, 2 November 2024
including flunarizine, mefloquine, and efavirenz. Another notable agent is rimonabant, a cannabinoid receptor antagonist marketed as an anti-obesity agent which...
5 KB (476 words) - 16:05, 11 October 2024
Naloxone Naltrexazone Naltrexonazine Naltrexone Naltrindole Naringenin Noribogaine Oxilorphan Pawhuskin A Rimonabant Quadazocine Samidorphan Taxifolin...
116 KB (11,202 words) - 23:02, 7 November 2024
Federal Analogue Act Hexahydrocannabivarin Medical cannabis Parahexyl Rimonabant (synthetic CB1 antagonist) Tetrahydrocannabiorcol (Δ9-THCC, (C1)-Δ9-THC)...
15 KB (1,380 words) - 15:59, 11 July 2024
Naloxone Naltrexazone Naltrexonazine Naltrexone Naltrindole Naringenin Noribogaine Oxilorphan Pawhuskin A Rimonabant Quadazocine Samidorphan Taxifolin...
174 KB (16,192 words) - 23:17, 11 November 2024
adverse cardiovascular risk profile. Similarly, the appetite suppressant rimonabant (a cannabinoid receptor antagonist) had to be withdrawn when it was linked...
14 KB (1,551 words) - 01:49, 26 August 2024
Naloxone Naltrexazone Naltrexonazine Naltrexone Naltrindole Naringenin Noribogaine Oxilorphan Pawhuskin A Rimonabant Quadazocine Samidorphan Taxifolin...
34 KB (3,196 words) - 20:33, 10 November 2024
depression, and thoughts of suicide in patients treated with the now-withdrawn rimonabant, another CB1 antagonist that was also under development by Sanofi-Aventis...
5 KB (399 words) - 03:26, 9 October 2024
UR-144 WIN 55,212-2 Yangonin Inverse agonists AM-251 INV-202 Monlunabant Rimonabant Surinabant Taranabant TM-38837 Zevaquenabant Antagonists AM-6545 Cannabidiol...
122 KB (12,157 words) - 15:23, 12 November 2024
clinical use was apparently halted shortly after the related CB1 antagonist rimonabant was discontinued in November 2008,[when?] due to the reports of severe...
4 KB (275 words) - 01:42, 4 February 2024
serotonergic psychedelics as well. Cannabinoid CB1 receptor antagonists like rimonabant, drinabant, and surinabant have been found to block or reduce the psychoactive...
35 KB (3,822 words) - 04:32, 14 November 2024
Naloxone Naltrexazone Naltrexonazine Naltrexone Naltrindole Naringenin Noribogaine Oxilorphan Pawhuskin A Rimonabant Quadazocine Samidorphan Taxifolin...
51 KB (4,620 words) - 00:16, 13 November 2024
UR-144 WIN 55,212-2 Yangonin Inverse agonists AM-251 INV-202 Monlunabant Rimonabant Surinabant Taranabant TM-38837 Zevaquenabant Antagonists AM-6545 Cannabidiol...
69 KB (7,678 words) - 05:46, 11 November 2024
Naloxone Naltrexazone Naltrexonazine Naltrexone Naltrindole Naringenin Noribogaine Oxilorphan Pawhuskin A Rimonabant Quadazocine Samidorphan Taxifolin...
124 KB (11,483 words) - 03:52, 11 November 2024
endocannabinoids bind to both receptor types. CB1 selective antagonists such as rimonabant are used for weight reduction and smoking cessation. A substantial number...
42 KB (4,331 words) - 16:48, 2 November 2024
Naloxone Naltrexazone Naltrexonazine Naltrexone Naltrindole Naringenin Noribogaine Oxilorphan Pawhuskin A Rimonabant Quadazocine Samidorphan Taxifolin...
116 KB (11,944 words) - 17:09, 1 November 2024
effects while retaining therapeutic efficacy. GAT100 Org 27569 PSNCBAM-1 Rimonabant US 11484537, Piazza PV, Fabre S, Metna M, Monlezun S, Busquet-Garcia A...
4 KB (297 words) - 08:14, 8 November 2024
Naloxone Naltrexazone Naltrexonazine Naltrexone Naltrindole Naringenin Noribogaine Oxilorphan Pawhuskin A Rimonabant Quadazocine Samidorphan Taxifolin...
143 KB (13,850 words) - 02:31, 12 November 2024